Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) has appointed Dr. Amie Phinney, PhD, MBA, as president and CEO, effective August 1, 2026. Sébastien Plouffe, founder and CEO, will assume the position of executive chairman of the board.
Dr. Phinney joined Defence as a strategy and business advisor in July 2025 and was appointed to the board of directors in September 2025. She brings more than two decades of international leadership experience spanning pharmaceutical research and development, biotechnology company creation, corporate strategy, business development, and commercialization.
In a statement, Sébastien Plouffe, executive chairman of Defence, commented, “Over the past year, Amie has demonstrated exceptional leadership, strategic vision, and an unwavering commitment to Defence’s mission. She has played an instrumental role in refining our corporate strategy, expanding our scientific and commercial vision, building the foundation for new strategic partnerships, and positioning Defence for its next phase of growth. The board is confident that she is the right leader to guide the company as we accelerate the development of the Accum platform, expand our therapeutic pipeline, and pursue strategic partnerships.”
